Algernon Logo 1.png
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
27 mai 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an...
Algernon Logo 1.png
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
17 mai 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study
12 mai 2021 07h15 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
11 mai 2021 07h01 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil
26 avr. 2021 08h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
08 avr. 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
06 avr. 2021 08h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil
31 mars 2021 08h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 31, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
29 mars 2021 07h02 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
17 mars 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...